Home › Upcoming votes › REVIVA PHARMACEUTICALS HOLDINGS, INC.
Prior-year votes at REVIVA PHARMACEUTICALS HOLDINGS, INC. → 2025-2026 season, in the search
The deadline as the proxy statement states it: “voting facilities are available now and will be available 24 hours a day until 11:59 p.m., Eastern Time, on December 17, 2026”. Shares held through a bank, a broker or a company plan can have a different deadline; the voting instruction form says.
Read the proxy statement on EDGAR
Summary, checked against the proxy statement. Each point is backed by a passage of the filing, shown under the point; figures under “Last year’s votes” come from the company’s Form 8-K. Read the proxy statement before relying on it.
Annual meeting: five directors, auditor ratification, say-on-pay, a reverse stock split proposal and an adjournment proposal, all with a board recommendation of FOR.
“To adopt and approve an amendment to the Certificate of Incorporation to effect a reverse stock split of the Company's issued shares of common stock, at a specific ratio, ranging from one-for-two (1:2) to one-for-one hundred (1:100), at any time prior to December 31, 2027” Find it in the filing
“suspended our common stock from trading on Nasdaq as of the open of trading on May 14, 2026, and Nasdaq filed a Form 25 on July 10, 2026 pursuant to Rule 12d2-2(b) to strike our common stock from listing on Nasdaq and/or withdraw registration on Nasdaq.” Find it in the filing
“The purpose for seeking approval to effect the Reverse Split is to increase the market price of our common stock to meet the Initial Listing Minimum Bid Price Requirement of Nasdaq or the comparable requirements of any other National Exchange on which we may seek to uplist.” Find it in the filing
“The Board reserves the right to elect to abandon the Reverse Split Charter Amendment and the Reverse Split at any of the Approved Split Ratios if it determines, in its sole discretion, that the Reverse Split is no longer in the best interests of the Company and its stockholders.” Find it in the filing
“16,955,524 shares of our common stock issuable upon exercise of common warrants, with a weighted-average exercise price of $5.90 per share” Find it in the filing
“The Board has decided, consistent with the vote of our stockholders at our 2024 Annual Meeting of Stockholders, to hold this non-binding say-on-pay vote on an annual basis.” Find it in the filing
“The Annual Meeting will be held virtually via the Internet at www.virtualshareholdermeeting.com/RVPH2026.” Find it in the filing
“effective June 3, 2025, Moss Adams merged with Baker Tilly, with the combined audit practices of the firms operating post-merger as Baker Tilly US, LLP” Find it in the filing
“ranging from one-for-two (1:2) to one-for-one hundred (1:100), at any time prior to December 31, 2027” Find it in the filing
Last year’s proxy statement, page 2: “ranging from one-for-two (1:2) to one-for-twenty (1:20), at any time prior to December 31, 2026”
“To approve an amendment to the Company's Amended and Restated Certificate of Incorporation, as amended (the Certificate of Incorporation"), to increase the Company's authorized shares of common stock from 315,000,000 to 515,000,000”
Last year’s proxy statement, page 2: “To approve an amendment to the Company's Amended and Restated Certificate of Incorporation, as amended (the Certificate of Incorporation"), to increase the Company's authorized shares of common stock from 315,000,000 to 515,000,000”
“suspended our common stock from trading on Nasdaq as of the open of trading on May 14, 2026” Find it in the filing
Last year’s proxy statement, page 40: “On May 13, 2025, we received a written notice from the Listing Qualifications Department (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") indicating that the Company is not in compliance with the $1.00 Minimum Bid Price requirement”
Ballot read from the proxy statement and checked. As listed in REVIVA PHARMACEUTICALS HOLDINGS, INC.’s proxy statement, with the board’s recommendation on each item.
| # | Item | Proposed by | Board recommends | Last year (same kind of item) |
|---|---|---|---|---|
| 1 | Election of directors Director election |
Board | For | 5 nominees; support 70% to 83% |
| 2 | Ratification of Baker Tilly US, LLP as auditor Auditor |
Board | For | 95% support |
| 3 | Advisory vote on executive compensation Say on pay |
Board | For | 71% support |
| 4 | Reverse stock split charter amendment | Board | For | — |
| 5 | Adjournment of the Annual Meeting Adjournment |
Board | For | — |
From REVIVA PHARMACEUTICALS HOLDINGS, INC.’s Form 8-K, filed December 23, 2025, for the meeting held December 18, 2025 (read it on EDGAR). Support is the share of votes cast that were FOR: abstentions and broker non-votes are left out.
| Item | Support (of votes cast) | Reported outcome |
|---|---|---|
| Elect Director: Laxminarayan Bhat | 83% | — |
| Elect Director: Parag Saxena | 71% | — |
| Elect Director: Richard Margolin | 76% | — |
| Elect Director: Purav Patel | 70% | — |
| Elect Director: Les Funtleyder | 76% | — |
| 2. Proposal to ratify the appointment of Baker Tilly US, LLP as the Company's independent registered public accounting firm for the Company' | 95% | Approved |
| 3. Proposal to approve, on an advisory basis, the executive compensation of the Company's named executive officers | 71% | Approved |
| 4. Proposal to approve the Increase in Authorized Charter Amendment to increase the Company's authorized shares of Common Stock from 315,000 | 62% | Approved |
| 5. Proposal to approve the Reverse Split Charter Amendment to effect a reverse stock split of the Company's issued shares of Common Stock, a | 68% | Approved |
The meeting facts and ballot come from the SEC proxy filings listed above. Ballots are read from the proxy statement and checked against the filing’s own text; when that check does not pass, the page shows “see the proxy statement” instead of a ballot. Last year’s figures are the company’s official Form 8-K results and the managers’ Form N-PX reports. Nothing on this page predicts how any shareholder will vote, and it is not investment advice. How this works.